Stock Analysis of Corbus Pharmaceuticals HLDG (CRBP)

Loading ...

Birds Eye View of Corbus Pharmaceuticals HLDG

Birds's Eye

Technical Analysis of Corbus Pharmaceuticals HLDG

Stock Analysis of Corbus Pharmaceuticals HLDG (CRBP) - Birds Eye View

1W 2W 1M 3M 1Y 2Y 5Y

Overview

Code	CRBP
Close	42.80
Change	1.30 / 3.13 %
Volume	166849
Vol Change	-57060.00 / 25.48 %
Industry	Biotechnology
Sector	Healthcare

AIO Strength Index

Technical Strength	Mild Bullish
Growth Index	Poor Growth Stock
Value Index	Poor Value Stock
Profitability Index	Poor Profitability Stock
Stability Index	Poor Stability Stock

Fundamental View of Corbus Pharmaceuticals HLDG

PE (TTM)

-6.79

Very Poor

Price / Book

9.86

Very Poor

Price / Sales

169.92

Very Poor

Piotroski F Score

2.0

Poor

Market Cap

457390 K

Enterprise Value

4379.31 M

All Financial Ratio's

ROA (TTM)

-59.08

Very Poor

ROE (TTM)

-145.07

Very Poor

Net Margin (TTM)

-2500.94

Very Poor

Revenue

%

Net Profit

12.08 %

-47460.97 K

Debt to Equity

-2.56

Very Poor

Altman Z Score

-21.62

Very Poor

Quick Ratio

0

Poor

Cash Ratio

0.430

Poor

Financial Statement Analysis

Highs/Lows of Corbus Pharmaceuticals HLDG

Period	Old price	Stock Return	S&P 500 Returns	High	Low	High Date	Low Date
One Week	45.02	4.93 %	0.513 %	46.25	41.275	28-May-24	31-May-24
Two Week	45.0	4.89 %	0.486 %	50.42	40.36	21-May-24	24-May-24
One Month	37.04	15.55 %	4.80 %	50.42	36.6	21-May-24	01-May-24
Three Month	30.9	38.51 %	3.56 %	50.42	30.3648	21-May-24	01-Mar-24
Six Months	6.69	539.76 %	15.54 %	50.42	4.99	21-May-24	12-Dec-23
One year	9.47	351.95 %	26.26 %	50.42	3.0334	21-May-24	13-Nov-23
Two year	9.102	370.23 %	27.72 %	50.42	2.11	21-May-24	10-Mar-23
Five year	210.3	79.65 %	91.77 %	50.42	2.11	21-May-24	10-Mar-23

Technical View of Corbus Pharmaceuticals HLDG

RSI

51.85

Neutral

MACD

1.09

Mild Bearish

ADX

25.48

Mild Bullish

Super Trend

38.06

Mild Bullish

Williams %R

-75.75

Strong Bullish

CCI

-12.46

Neutral

Technical Analysis Deep Dive

EMA 5

42.91

Mild Bearish

EMA 15

43.01

Whipsaw

EMA 50

39.44

Bullish

EMA 100

33.04

Strong Bullish

SMA 100

32.48

Strong Bullish

SMA 200

19.17

Bullish

SMA 5 / 20

43.10 / 43.15

Strong Bearish

SMA 15 / 50

43.97 / 39.92

Strong Bullish

SMA 50 / 200

39.92 / 19.17

Strong Bullish

MA Analysis Deep Dive

Charts of Corbus Pharmaceuticals HLDG

Returns of Corbus Pharmaceuticals HLDG with Peers

Period / Stock	CRBP	ACIU	EHAB	VYGR
1 Week	-4.93%	31.36%	3.96%	2.07%
1 Mth	15.55%	87.50%	-8.92%	7.42%
3 Mth	38.51%	28.45%	2.11%	0.962%
6mth	539.76%	40.48%	-13.79%	15.70%
1 Year	351.95%	113.30%	-14.59%	-26.25%
2 Year	370.23%	48.09%	-	38.61%
5 Years	-79.65%	-8.10%	-	-61.49%
charts	-

View All Together in Chart Inline Tile

Compare Fundamentals of Corbus Pharmaceuticals HLDG with Peers

Ratio / Stock	CRBP	ACIU	EHAB	VYGR
PE	-6.79	-7.77	-5.54	-30361.36
P/B	9.86	2.93	0.774	395.16
ROA	-59.08	-33.34	-6.95	-0.861
ROE	-145.07	-37.73	-14.12	-1.30
Debt To Equity	-2.56	0.0042	0.843	0.0135
Revenue	0 %	1000.00 99.97 %	1048.80 M 3.17 %	158397 K 287.21 %
Net Income	-47460.97 K 12.08 %	-68238.00 K 3.55 %	-169300.00 K 370.88 %	52309.00 K 212.72 %

Technicals of Corbus Pharmaceuticals HLDG with Peers

Technical / Stock	CRBP	ACIU	EHAB	VYGR	-
ADX	25.48	41.85	23.57	12.91
CMF	0.142	0.351	0.0095	-0.0237
MFI	40.51	96.41	65.87	38.93
RSI	51.85	78.20	47.65	51.64
MACD Abv Signal	False	True	True	False
Price Above 50 MA	True	True	False	False	-
Price Above 200 MA	True	True	False	True	-

About : Corbus Pharmaceuticals Holding

Address : 500 River Ridge Drive, Norwood, MA, United States, 02062
Tel : 617 963 0100
URL : https://www.corbuspharma.com
Code : CRBP, ISIN : US21833P1030, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 11_Nov_2014
Employee Count : 19

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Note : All Data Generated at the End of Trading Hours (EOD Data)